Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial

Related

• 

  Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials

  Karl G. Csaky, MD, PhD

  Annual Meeting Talks

  2018

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Single Intraoperative Subconjunctival Triamcinolone Acetonide Injection Versus 4-6-Week Topical Steroid Taper Following Vitreoretinal Surgery

  Elizabeth A Atchison, MD

  Annual Meeting Talks

  2018